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Mesenchymal stromal cells (MSC) have potent immunomodulatory properties which have led to 
them being considered as a novel therapeutic modality across a wide range of clinical areas including 
conditions such as steroid refractory paediatric graft versus host disease (GVHD) where they are 
licensed in New Zealand and Canada. Indeed, more recently adipose derived MSC have also been 
shown to be clinically effective in a phase 3 clinical trial in fistulising Crohn’s disease 
(http://www.tigenix.com/en/pages/11/news). The pleiotropic actions of MSC in modulating the 
immune system are often presented as a strength although from a clinical and regulatory 
perspective a more defined mechanism of action may be preferable. The study by Lee et al presents 
data on the efficacy of murine MSC in a model of concanavalin A (Con A) induced hepatitis as well as 
novel insights into their mechanism of action. Early assumptions around cell therapies included their 
homing to the injured organ whereupon correction of tissue damage would occur either directly by 
reconstitution of missing cells or indirectly by amelioration of immune-mediated damage.  
 
Homing of MSC to sites of inflammation 
This study is notable in that there does not appear to be increased homing to the injured liver, and 
indeed most of the MSC appear to lodge in the lung from where they are reported as exerting their 
beneficial effects. Lodging of MSC in the lung is well recognised and is best described as a passive 
process in contrast to the active homing reported to inflamed organs
1
. Groups have shown 
previously that either blockade or knock-out of integrin receptors reduces engraftment and vascular 
rolling of MSC in the setting of injured myocardium2 suggesting that the engraftment of MSC within 
target tissues is an active process. Aldridge et al reported that there was increased MSC binding both 
ex vivo and in vivo to injured liver which was mediated by a highly ordered interaction between their 
cell surface receptors CD44 and β1−integrin and cognate receptors such as VCAM on hepatic 
sinusoidal endothelium3.  
  
Thus, this lack of increased hepatic homing is surprising, although this may relate to their usage of 
Carboxyfluorescein succinimidyl ester (CFSE) as a fluorescent label to perform cellular quantification 
which has relatively limited resolution. Other methods for quantifying the homing efficiency of MSC 
such as measurement of the relative level of radioactivity in excised tissues and organs4 or the 
number of fluorescently labelled cells in a defined number of microscopic fields
5
 are more accurate, 
with even more detailed quantification of MSC achieved by labelling with super paramagnetic iron 
oxide nanoparticles or quantum dots. Lee et al quantified distribution of MSC at 12 and 24 hours 
after intravenous administration, which is relevant as MSC are known to redistribute after their 
initial localisation to the lungs to injured organs such as the heart
6
 and liver, spleen, kidney, and 
bone marrow
7
. This observation has also been reported after clinical administration to MSC to 
patients with liver cirrhosis in which cells re-localised to the liver and spleen8. 
An additional consideration when examining MSC localisation within the first 24 hours is their 
positioning in relation to tissue blood vessels as there is an important distinction between cells 
passively entrapped within blood vessels and those that have trans-migrated into the tissue. 
That this homing to sites of tissue damage has been reported in a range of inflammatory conditions 
also raises the possibility that mobilisation of endogenous MSC may serve as a response to reduce 
aberrant tissue inflammation. However, whilst some groups report increased MSC mobilisation in 
the setting of injury such as intimal hyperplasia9 or cytokine stimulation10 this is not a universal 
finding and thus there is uncertainty regarding its biological relevance. 
 
Relationship between homing of MSC to site of injury and efficacy  
Increased homing and engraftment of MSC to the injured myocardium has been reported to 
enhance their reparative contribution2, in keeping with the findings of other studies, although this is 
not a universal finding as other groups report a systemic or distant effect of MSC on the desired 
  
target organ without any significant homing to it11. These observations are not mutually exclusive 
and raise questions regarding the mechanism(s) of action of MSC and also about practical issues 
such as the optimal route of delivery/administration. 
Most notably Zanotti et al reported that alginate-encapsulated MSC injected subcutaneously, which 
were not able to migrate, exerted a potent immunosuppressive effect in vivo in models of cutaneous 
antigen-specific immune-mediated model of injury and acute GVHD, which was superior to that seen 
with systemically administered MSC
11
. Whilst this may reflect prolongation of in vivo viability of MSC 
by alginate encapsulation it also demonstrates that MSC homing to specific organs is not always 
needed to control inflammation and that, in certain settings their immunosuppressive effects may 
be mediated by the release of systemically acting soluble factors. One possible candidate is TSG-6 
which has been previously reported to mediate the therapeutic effects of MSC in models of 
encephalitis and colitis where cells have not been able to cross the blood-brain barrier
12
. 
In this paper MSC are hypothesised to mediate their beneficial effects on the liver by polarising 
macrophages to an anti-inflammatory M2 phenotype, which is achieved by the release of MSC-
derived IL1 receptor antagonist (IL1Ra). Ortiz et al previously determined that IL1Ra was present in a 
sub-population of MSC and that MSC administration was more effective than recombinant IL1Ra 
delivered via adenoviral infection or osmotic pumps in a model of bleomycin (BLM)-induced lung 
injury13. MSC administration protected lung tissue from BLM-induced injury by interfering with the 
action/production of two key proinflammatory cytokines in lung, IL-1α and TNF-α. These factors 
may also be of relevance in liver disease as they drive the expression of endothelial adhesion 
molecules thus accentuating the early inflammatory response. It would also be interesting to 
understand the factors regulating the release of IL1Ra as the immunosuppressive effects of MSC are 
critically influenced by their sensing of the environment; in the presence of inflammation with high 
levels of cytokines such as TNF-a and IFN-γ MSC can become activated and adopt an immune-
suppressive phenotype (MSC2)
14
.  Thus, it would be informative to establish the constitutive 
  
production of IL1-Ra by MSC and/or whether cells need to be primed/infused into an inflammatory 
environment for this release to occur.  
Indeed, although Lee et al report co-localisation of macrophages and MSC in the lungs, this does not 
preclude interactions elsewhere such as the liver and the circulation as evidenced by the efficacy of 
alginate-encapsulated MSC placed subcutaneously. The influence of MSC on macrophage polarity is 
well-established, with factors such as MSC-derived IL6 polarising monocytes to anti-inflammatory 
M2 macrophages that secrete IL10
15
. However, in the absence of IL6 and a pro-inflammatory milieu 
MSC can induce polarisation of monocytes toward pro-inflammatory M1 macrophages, thus it would 
be important to establish the role of IL1-Ra release alongside other known factors in this finely 
calibrated system. There was no effect of MSC on induction of regulatory T cells in this study as 
determined by hepatic expression of FoxP3, which is a surprise given that this effect is closely linked 
to their polarisation of M2 macrophages. It would perhaps have been informative to look for the 
presence of CD4+CD25+FoxP3+ regulatory T cells in digested livers to provide a more detailed 
quantitative analysis rather than relying on gene expression alone. 
 
Relevance to clinical practice 
MSC used for these studies were heterogeneous bone marrow derived plastic adherent cells isolated 
from BALBc mice, and it would be important therefore to establish to what extent these findings 
would hold true for human MSC and also MSC isolated from Bl/6 mice for which mechanisms of 
immunosuppression are different. Specifically, production of nitric oxide (NO) is restricted to BALBc 
derived MSC whereas indoleamine 2,3 dioxygenase (IDO) is required for the action of human, and 
also Bl/6, derived MSC14. It would be important to establish whether human MSC therefore need to 
be primed prior to infusion to ensure an anti-inflammatory effect, or is a pro-inflammatory 
environment provide the necessary stimulus? 
  
In this study 104 infused MSC were not found to be effective, with a dose of 105 being needed – this 
equates to a dose of 2.5 x 10
6
 cells/kg, which is in keeping with the doses being contemplated for 
systemic administration in patients. The likeliest route of administration in patients will be 
intravenous, which would appear to be effective, as well as the most expedient route. The finding 
that large numbers of MSC aggregate in the lungs with no adverse effects is reassuring and in 
keeping with prior studies in patients with cirrhosis. Ultimately, the question around site of action of 
MSC will be answered by clinical studies utilising state of the art non-invasive imaging to correlate 
the extent of hepatic homing with clinical efficacy. In the meantime the first challenge is to 
demonstrate efficacy with MSC in inflammatory liver disease, and hopefully upcoming studies in 
patients with primary sclerosing cholangitis will start to shed light on this 
(http://fp7merlin.eu/project/the-research-plan/). 
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